TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
IPO Year:
Exchange: NASDAQ
Website: therapeuticsmd.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $3.00 → $2.50 | Buy | HC Wainwright & Co. |
| 11/12/2021 | $4.00 → $3.00 | Buy | HC Wainwright & Co. |
- Robust Strategic Alternatives Process Continues - TherapeuticsMD, Inc. (NASDAQ:TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women's healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company's Interim Co-Chief Executive Officers and Co-Principal Executive Officers. Dr. Bernick and Mr. Glickman succeed Mr. Hugh O'Dowd as the Company's Chief Executive Officer. Prior to this appointment, Dr. Bernick, the Company's co-founder, served as Chief Scientific and Medical Officer, and Mr. Glickman served as Chief Business Officer. The Company also announced that the Board of Directors appointed The Honorable Tommy Thompson, w
Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the world's first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Medtronic, and Inamed Corporation, was pivotal in raising over $350 million from t
- Mr. O'Dowd to succeed Robert G. Finizio, effective on or before December 31, 2021 - - Mr. Finizio appointed Vice Chair of the Board - TherapeuticsMD, Inc. (NASDAQ:TXMD) (TXMD or the Company), an innovative, leading women's healthcare company, today announced key leadership changes, including the appointment of Hugh O'Dowd, the Company's current President, as the Company's Chief Executive Officer and member of the board of directors. Mr. O'Dowd will succeed Robert G. Finizio, the Company's Co-founder and current Chief Executive Officer, effective on or before December 31, 2021. Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors. "I wan
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced the appointment of Mark Glickman as the Company's Chief Business Officer. Mr. Glickman previously served as Chief Commercial Officer of Esperion and Aralez Pharmaceuticals, and Executive Vice President, Sales and Marketing, of Auxilium Pharmaceuticals, among other global pharmaceutical roles. Mr. Glickman received his MBA in Finance and International Management from New York University and his BA from State University of New York College at Oswego. Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) As a material inducement to Mr. Glickman's acceptance of the appointment, Therapeutics
– O'Dowd brings 25+ years of experience in senior leadership roles with leading pharmaceutical companies – TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced the appointment of Hugh O'Dowd as President. Mr. O'Dowd succeeds John C.K. Milligan, IV, who the Company recently appointed as Chief Executive Officer of its vitaCare Prescription Services business. "I am delighted to welcome Hugh as President of TherapeuticsMD. Hugh has a significant operating and strategic history with both large and small pharmaceutical companies including over 20 years at Novartis, where he navigated some of the most challenging payor and commercial environments
Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-6) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 12/28/2021. Application Category: NDA, Application Number: 210132, Application Classification: Efficacy
Submission status for THERAPEUTICSMD INC's drug IMVEXXY (SUPPL-2) with active ingredient ESTRADIOL has changed to 'Approval' on 11/16/2021. Application Category: NDA, Application Number: 208564, Application Classification: Labeling
Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-3) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 06/22/2021. Application Category: NDA, Application Number: 210132, Application Classification: Labeling
Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-1) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 06/22/2021. Application Category: NDA, Application Number: 210132, Application Classification: Labeling
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
HC Wainwright & Co. reiterated coverage of TherapeuticsMD with a rating of Buy and set a new price target of $2.50 from $3.00 previously
HC Wainwright & Co. reiterated coverage of TherapeuticsMD with a rating of Buy and set a new price target of $3.00 from $4.00 previously
- Mayne Pharma gains exclusive U.S. commercialization rights for TXMD's products and acquires certain assets - - TXMD received approximately $153.1 million at closing; portion of proceeds used to repay all outstanding indebtedness under Sixth Street facility and redeem all outstanding preferred equity - - TXMD is eligible to receive up to $30.0 million in milestone payments and a minimum of $42.6 million in royalty payments - TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women's healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-lis
- Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the third quarter ended September 30, 2022. "Our products continue to be adopted by healthcare providers and patients, and we continue to believe that they represent a significant opportunity. Our prescriber bases grew, and we added around 1,500 new prescribers for ANNOVERA and around 1,600 for IMVEXXY. Total quarterly prescriptions for both products remained relatively stable compared to the second
- Quarterly total net revenue of $28.6 million - - ANNOVERA® TRx of 9,329, an increase of 28% over Q2 2021 - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the Second Quarter ended June 30, 2022. "We saw solid revenue growth during the quarter, with an increase of 24% over the prior year period, while also experiencing a 21% decrease in operating expenses. The U.S. Food and Drug Administration's recent approval of our supplemental new drug application for ANNOVERA has significantly enhanced our ability to meet demand for the product.
-Executive Management to Host Conference Call on August 15, 2022, at 8:30 a.m. ET- TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it will report its second quarter 2022 financial results on Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date: Monday, August 15, 2022 Time: 8:30 a.m. ET Audio Conference Line https://register.vevent.com/register/BI7d111b66df2f4e8f849bb6048c1fa4d1 Webcast Link:
- Quarterly total net product revenue of $19.3 million - - ANNOVERA® TRx of 8,014, an increase of 27% over Q1 2021 - - Announced and completed vitaCare divestiture in five weeks - - Conference call scheduled for 4:30 p.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the first quarter ended March 31, 2022. "Our revenue performance during the quarter was impacted by ANNOVERA manufacturing challenges as anticipated, but we believe these obstacles peaked in the first quarter of 2022 and expect incremental improvement as the year progresses. I'm also pleased to report that the $1
-Executive Management to Host Conference Call on May 16, 2022, at 4:30 p.m. ET- TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it will report its first quarter 2022 financial results on Monday, May 16, 2022, after the closing of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date: Monday, May 16, 2022 Time: 4:30 p.m. ET Telephone Access (US): 866-665-9531 Telephone Access (Intl): 724-987-6977 Conference ID: 3179996 Webcast: https://edge.medi
- Reached definitive agreement to fully divest vitaCare business unit enabling greater focus on achieving leadership position in women's healthcare - - Amended credit terms with Sixth Street in support of a new capitalization plan - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the fourth quarter ended December 31, 2021. "We spent the past three months executing on four key priorities set forth last quarter, and today we announced that we have accomplished two of them. With the definitive agreement to fully divest our vitaCare busines
-Executive Management to Host Conference Call on March 10, 2022, at 8:30 a.m. ET- TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it will report its fourth quarter 2021 financial results on Thursday, March 10, 2022, before the opening of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date: Thursday, March 10, 2022 Time: 8:30 a.m. ET Telephone Access (US): 866-665-9531 Telephone Access (Int'l): 724-987-6977 Conference ID: 6988467 Webcast: https://ed
- Quarterly total net product revenue of $24.5 million, an increase of 41.1% over Q3 2020 - - ANNOVERA® TRx of 8,351, an increase of 62.7% over Q3 2020 - - Cost savings initiative to reduce SG&A by $40 million in 2022; anticipated additional savings of approximately $20 million annualized tied to the divestiture of vitaCare - - Hugh O'Dowd, President, to become Chief Executive Officer; Robert Finizio appointed Vice Chair of the Board - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the third quarter ended September 30, 2021. In addi
-Executive Management to Host Conference Call on November 11, 2021 at 8:30 a.m. ET- TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TXMD" or the "Company"), an innovative, leading women's healthcare company, today announced that it will report its third quarter 2021 financial results on Thursday, November 11, 2021, before the opening of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date: Thursday, November 11, 2021 Time: 8:30 a.m. ET Telephone Access (US): 866-665-9531 Telephone Access (International): 724-987-6977 Conference ID: 6341637 Webcast: h
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(2.3) million, or $(0.20) per basic and diluted common share, a decrease of $5.4 million, compared to net loss from continuing operations of $(7.7) million, or ($0.74) per basic and diluted common share, for 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $1.8 million during the year ended Dec
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(567) thousand, or $(0.05) per basic and diluted common share, compared to a net loss of $(1.4) million, or $(0.13) per basic and diluted common share, for the third quarter of 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $547 thousand for the third quarter of 2024, a
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(1.05) million, or $(0.09) per basic and diluted common share, compared to a net loss of $(2.4) million, or $(0.24) per basic and diluted common share, for the second quarter of 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $234 thousand for the second quarter of 2024, a
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(0.8) million, or $(0.07) per basic and diluted common share, compared to net loss from continuing operations of $(2.3) million, or $(0.24) per basic and diluted common share, for 2023. License and Service Revenues from Continuing Operations Gross license royalties totaled approximately $1.2 million under the Mayne License Agreement for the three months en
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023. "We continue to explore a variety of strategic alternatives with the goal of maximizing value for our shareholders," stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Full Year 2023 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share, compared to net income from continuing operations of $1.1 million, or
Focus remains on cost control to maximize the value of our royalty assets Company announces evaluation of strategic alternatives TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023. "As the Company continues its transition into a royalty-based business, we remain committed to cost control to maximize the value of our royalty assets," stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Third Quarter 2023 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $1.4 milli
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023. "The Company's transformation into a royalty-based business is ongoing. As we phase out our historical business operations, we remain focused on reducing costs and conserving cash," stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Second Quarter 2023 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $2.4 million for the quarter ended June 30, 2023, or $(0.24) per basic and diluted common share, compared to a net loss f
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $2.3 million for the quarter ended March 31, 2023, or $0.24 per basic and diluted common share, compared to a net loss from continuing operations of $17.9 million, or $2.08 per basic and diluted common share, for the comparable period in 2022. License and Service Revenues from Continuing Operations License and service revenues from continuing operations, which are r
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022. "As a result of the transaction with Mayne Pharma Group Limited (ASX: MYX) ("Mayne Pharma") that closed at year-end, in which TherapeuticsMD granted Mayne Pharma an exclusive license to commercialize TherapeuticsMD's products in the United States, we repaid our debt, redeemed our outstanding preferred stock, eliminated our commercial and manufacturing infrastructure, and downsized our remaining operations," said Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. "We look forward
- Mayne Pharma gains exclusive U.S. commercialization rights for TXMD's products and acquires certain assets - - TXMD received approximately $153.1 million at closing; portion of proceeds used to repay all outstanding indebtedness under Sixth Street facility and redeem all outstanding preferred equity - - TXMD is eligible to receive up to $30.0 million in milestone payments and a minimum of $42.6 million in royalty payments - TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women's healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-lis
10-Q - TherapeuticsMD, Inc. (0000025743) (Filer)
8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
10-K/A - TherapeuticsMD, Inc. (0000025743) (Filer)
8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
10-K - TherapeuticsMD, Inc. (0000025743) (Filer)
8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
SCHEDULE 13G - TherapeuticsMD, Inc. (0000025743) (Subject)
8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
10-Q - TherapeuticsMD, Inc. (0000025743) (Filer)
8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
SC 13G - TherapeuticsMD, Inc. (0000025743) (Subject)
SC 13D/A - TherapeuticsMD, Inc. (0000025743) (Subject)
SC 13D/A - TherapeuticsMD, Inc. (0000025743) (Subject)
SC 13D/A - TherapeuticsMD, Inc. (0000025743) (Subject)
SC 13D - TherapeuticsMD, Inc. (0000025743) (Subject)
SC 13G - TherapeuticsMD, Inc. (0000025743) (Subject)
SC 13D/A - TherapeuticsMD, Inc. (0000025743) (Subject)
SC 13G - TherapeuticsMD, Inc. (0000025743) (Subject)
SC 13G/A - TherapeuticsMD, Inc. (0000025743) (Subject)
SC 13G/A - TherapeuticsMD, Inc. (0000025743) (Subject)